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Gene products of the major histocompatibility complex (MHC) t are important in 
many, if not all, cell-cell interactions involving immune responses of T  cells (1). These 
MHC antigens can be classified into two kinds of molecules based on functional and 
structural considerations (2). Class I molecules (e.g., H-2K and HLA-A) are composed 
of two chains of 44,000 and  12,000  mol wt;  they are expressed on virtually all cells 
and are the predominant antigens recognized by cytotoxic T  cells. Class II molecules 
(e.g., H-2IA and HLA-DR) are composed of two chains of ~34,000 and ~28,000 mol 
wt;  they  are  preferentially  expressed  on  B  cells  and  macrophages  and  are  the 
predominant  antigens  that  stimulate  T  cell  proliferation.  There  is  extraordinary 
diversity of both the class I and class II molecules, which generally are expressed on 
a single donor's cells. This has apparently been achieved during the course of  evolution 
by two distinct mechanisms:  gene duplication, and generation of polymorphism for 
each of those duplicated genes (3, 4). Thus, for example, in humans, the HLA-A, -B, 
and -C loci each code for class I molecules, and there are at least seven alleles for each 
locus; so that many donors have six distinct class I molecules. It is difficult to explain 
this evolutionary acquisition of a diverse repertoire of structurally similar cell surface 
antigens by random drift. Instead, it is attractive to hypothesize that  because these 
antigens  are  involved  in  immune  recognition,  the  possession  of such  diverse  self 
structures confers on the individual a  better immune response to a  wide variety of 
foreign antigens (5, 6). 
Polymorphism has been shown, and gene duplication suggested, for class I molecules 
in man (HLA-A, -B, and -C), for class I molecules in the mouse (H-2K, -D, and -L), 
and for class II molecules in the mouse (H-2IA and H-2E/C) (4, 7, 8). In contrast, for 
class II molecules in the human, the major emphasis has been on a single segregant 
series of B cell alloantigens:  HLA-DR. Recently, serologic (9-12) and structural  (13, 
14)  evidence have suggested the existence of several distinct  kinds of human  B cell 
antigens.  This study provides strong functional evidence for two distinct  segregant 
1Abbreviations used in  this paper: complete  medium,  RPMI-1640  medium  with  glutamine  that  was 
supplemented with penicillin (10 U/ml) and streptomycin (10 ~tg/ml);  CML, cell-medlated cytotoxicity; 
MHC, major histocompatibility complex; PHA, phytohemagglutinin;  PLT, primed  lymphocyte typing; 
SB, secondary  B cell. 
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series  of  B  cell  alloantigens.  Allogeneic  mixed  lymphocyte  responses  have  been 
exploited to identify five new histocompatibility antigens. These determinants, which 
we have designated secondary B cell (SB) antigens, are distinct from the DR antigens; 
however, both the  SB  and the  DR  antigens are encoded  in the same region of the 
MHC,  both  are  preferentially expressed  on  B  cells,  and  both  stimulate secondary 
allogeneic proliferative and cytotoxic responses. These data are consistent with  the 
interpretation that  the  SB  antigens and  DR  antigens are  products  of duplicated 
ancestral genes. 
Materials and Methods 
Human  Reagents.  Human  peripheral  blood  mononuclear cells  were  obtained  by  batch 
leukapheresis, separated by flotation on Ficoll (Pharmacia Fine Chemicals, Div. of Pharmacia, 
Inc., Piscataway, N. J.) -Hypaque (Winthrop Laboratories, New York),  and cryopreserved as 
previously described (15). Plasma from five or more normal males was pooled, frozen in aliquots 
at -20°C, and used as a normal plasma pool. Serotyping and HLA-D typing were performed 
by standard procedures (16). 
Lymphocyte Priming.  Responder and stimulator cells were thawed, washed, and resuspended 
in RPMI-1640 medium with glutamine (Grand Island Biological  Co.,  Grand Island, N.  Y.) 
that  was  supplemented with  penicillin (10  U/ml)  and streptomycin  (10 #g/ml)  (complete 
medium). 6  X  106 responding cells were  mixed with  3  x  106 irradiated  (2,000  rad;  cesium 
source) stimulator cells in a 25-cm 2 tissue culture flask in 8 ml ofcomplete medium supplemented 
with 0.5 ml of normal human plasma. The flask was incubated upright in 5(~ CO2-95% air at 
37°C for  10 d. Primed cells were either used fresh or after cryopreservation. 
Primed-Lymphocyte Typing (PLT).  2  x  104  primed  cells  were  cocultured  with  1  x  l0  s 
irradiated stimulator cells  in 0.2  ml of complete media with  15%  heat-inactivated human 
plasma. After 48 h, 1 #Ci of [3H]thymidine was added, the cells were harvested  18 h later, and 
[3H]thymidine incorporation was evaluated by counting beta emissions. 
Cell-mediated Cytotoxicity.  3  ×  106 primed cells  were  cocultured with  10  X  l0  s irradiated 
stimulator cells in 6 ml of complete media with 15% heat-inactivated human plasma in 25-cm 2 
tissue culture flasks for 5 d. The target cells and blocking cells used were either:  (a)  lympho- 
blastoid B cell lines that had been transformed with Epstein-Barr virus (17), or (b) peripheral. 
blood mononuclear cells that had been precultured for 3 d  in complete medium with  1:200 
dilution of phytohemagglutinin (PHA)  (M  form;  Grand Island Biological  Co.)--these cells 
were  generally >90% T  cells by analysis of E-rosette binding, surface immunoglobulin, and 
esterase staining and are therefore referred to as T  lymphoblasts. Targets were labeled by a 90- 
min incubation with  Na[SXCr]O4 (New  England Nuclear, Boston, Mass.).  Cytotoxicity was 
determined in a  standard 6-h  chromium-release assay  (15) using  1 ×  104  target  cells  and 
effector:target  ratios of 20:1 and 7:1. For cold-target-cell inhibition assays, effector  cells and 
unlabeled blocking cells  were  preincubated for  10  min before  the  addition of the  labeled 
targets; the effector:target cell ratio used was 20:1 and the blocker:target cell ratios were 60:1 
and 20:1. 
Data Analysis.  Proliferative data were calculated as the geometric mean and standard error. 
Data  were  expressed  as  percent  relative response.  For  primary proliferative responses,  the 
percent relative response was calculated as [(counts per minute for experimental)/(counts per 
minute for a pool of 10 allogeneic cells)[ X 100. For secondary proliferation, the percent relative 
response  was calculated as  [(counts per minute for unknown restimulating cell)/(counts per 
minute for the specific restimulating cell)] X 100. The geometric SE for this ratio was <1.2 for 
all data shown. For cytotoxic assays, percent specific lysis was calculated as [(counts per minute 
experimental) -  (counts per minute media)]/[(eounts per minute detergent)  -  (counts per 
minute media)]. Spontaneous release was always < 18% for B cells and <27% for T lymphoblasts. 
The arithmetic SE  for  percent specific  release  never exceeded  5%.  To assure objectivity in 
scoring positives and negatives in proliferative and cytotoxic assays, assignment was made by 
cluster analysis (18). This analysis tests  all  possible  assignments of donors as  positive and STEPHEN  SHAW,  ARMEAD  H.  JOHNSON,  AND  GENE  M.  SHEARER 
TABLE  I 
HLA Phenotype of Principal Donors Studied 
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HLA- 
Donor 
A  B  C  D  DR  MB  SB 
H9  1,2  7,8  -*  w2,3  w2,3  1,2  1,2 
MI4  1,2  7,8  -  w2,3  w2,3  1,2  3,4 
PMI  1,2  7,8  -  w2,3  w2,3  1,2  2,4 
S11  1,2  7,8  -  w2,3  w2,3  1,2  2,5 
W7  1,2  7,8  -  w2,3  w2,3  1,2  1,4 
R5  1,2  7,8  -  w3  w2,3  ND~  2,3 
BI7  1,2  7,8  -  w2,4  w2,4  1,3  2,4 
F2  1,2  7,8  -  w2,4  w2,4  1,3  4,5 
LI0  1,2  7,8  -  w2,2  w2  1  4 
P6  1,2  7,8  3  ND  w2,5  ND  4 
H7  1,2  7,8  -  ND  w3,?6  ND  4 
HI0  1,2  7,8  -  ND  w3  ND  4 
K4  1,2  7,8  -  ND  wl,3  2,?1  1 
F1  1,2  7,8  -  ND  w4,6  ?3  2,4 
FB6  25,31  15,40  3  w4,-  w4,4  3,?2  I,- 
FB 1 1  25,31  15,40  3  w4,-  w4,4  3,?2  4,- 
* -, indicates that no specificity was identified (blank);  for donors  FB6 and FBI 1, haplotype assignment 
was  made  by  family study,  and  therefore  blanks could  be  assigned  in  presence  of another  defined 
specificity. 
:]: ND, not done. 
negative  and  chooses  the  assignment  that  minimizes the  variability  within  the  positive  and 
negative clusters. 
Results 
In  order  to  use  cellular  responses  to  define  new  histocompatibility  antigens,  re- 
sponder lymphocytes were primed in vitro with stimulator cells with which they were 
matched for all known HLA antigens (A, B, C, D, DR, and MB). Table I summarizes 
the  HLA  phenotype  of  the  principal  donors  used:  14  individuals  of  phenotype 
A1,2,B7,8 and two siblings from an informative HLA recombinant family (19). HLA- 
A, -B, and -C, and DR antigens were analyzed by serotyping: MB antigens were also 
assigned by serotyping, as proposed by Duquesnoy et al.  (12). Assignment of HLA-D 
was by primary proliferative responses to homozygous typing cells. Assignment of SB 
antigens is based on studies described in this report and included here as a summary. 
Definition of Five New Antigens That Stimulate Secondary Proliferative Responses.  Among 
the AI,2,B7,8  donors, 22 different  combinations of responders and stimulators were 
identified in which the cells also shared D, DR, and MB.  Lymphoeytes were primed 
in vitro in all 22 combinations. As expected  on the basis of HLA-D matching, there 
was  little  primary  proliferative  response  in  these  combinations;  the  mean  relative 
response in these pairs was 8% compared  to a  mean autologous response of 3%, and 
a  mean  response  of 48%  among  unselected  combinations  of the AI,2,B7,8  donors. 
These 22 populations of primed lymphocytes were restimulated with cells from each 
of the  14  A1,2,B7,8  donors  (10  such  combinations  are  shown  for  a  representative 568  A  NEW  SEGREGANT  SERIES  OF  HUMAN  B CELL ALLOANTIGENS 
TABLE II 
Definition of Five New Alloantigens by PL T 
Priming  Primed 
antigens  cells 
Percent  relative  response  when  restimulated  with  cells  from  donor 
H9  MI4  PMI  SII  W7  R5  B17  F2  LIO  P6  H7  HI0  K4  FI 
Total 
counts 
per min- 
ute* 
X  10  :~ 
SBI  PMI  Hg~  100  38  3  20  120  45  6  12  4  6  5  2  112  5  17.2 
+§*  -  -  +  ....  +  - 
SI  I  H9  100  30  14  6  120  28  13  7  18  16  13  5  100  18  19.5 
+  --  --  +  ....  +  -- 
SB2  F2 BI7  75  10  72  77  4  92  100  4  9  6  6  31  34  78  16.0 
+  -  +  +  -  +  +  ....  + 
W7 H9  100  8  88  100  5  120  110  6  8  10  8  56  40  100  19.8 
+  --  +  +  -  +  +  ....  + 
SB3  PMI  M14  19  100  5  8  19  110  5  5  6  6  4  3  37  6  12.6 
-  +  -  _  +  ...... 
W7M14  8  10~  9  10  5  100  15  6  8  7  5  5  33  II  15.3 
-  +  -  -  +  ...... 
SB4  H9 W7  11  120  90  20  100  15  110  71  120  94  94  38  40  91  10.2 
-  +  -I-  -  +  +  +  +  +  +  -  -  + 
Sll  PMI  16  120  100  16  120  31  130  91  120  120  120  73  28  I|0  10,8 
--  +  +  --  +  +  +  +  +  +  +  --  + 
SB5  H9 SI 1  5  22  13  100  14  17  22  64  19  I I  19  7  23  15  26.8 
-  -  +  -  -  +  ..... 
BIT F2  27  13  4  120  17  16  4  100  9  6  9  5  46  6  53.6 
-  -  +  -  -  +  ..... 
DRwl  H9 K4  3  5  3  7  2  23  12  6  3  5  6  4  100  9  15.2 
........  +  - 
DRw2  F1  B17  85  97  59  80  67  84  100  3511  99  65  2  2  9  3  17.8 
+  +  +  +  +  +  +  -  +  +  -  -  _ 
I)Rw3  (+ SBI)  F2 W7  9(1  85  69  79  100  99  7  3  8  6  103  55  112  26  138 
+  +  +  +  +  +  -  -  -  +  +  +  - 
Drw4 (+ SBI)  H9 B17  3  12  9  7  10  5  10~O  60  20  20  17  4  21  72  17.4 
....  +  +  ....  + 
DR  antigens  2,3  2,3  2,5  2,3  2,3  2,3  2,4  2,4  2,2  2,5  3,76  3  1,3  4,6 
known 
SB  antigens  as-  1,2  3,4  2,4  2,5  1,4  2,3  2,4  4,5  4  4  4  (4)  I  2.4 
signed 
* Total counts per minute for the secondary response to the original priming cell. 
1: Designates the responding cells and the stimulating cells that were used to generate the primed cells. 
§ Designates assignment as positive (+) or negative (-) stimulation by cluster analysis. 
[I Designates the only individual in whom the PLT assignment of DR did not correlate with the serotyping. 
experiment  in Table  II).  Despite  the absence of strong proliferation  during priming, 
many  of the primed  lymphocyte  reagents  showed  strong specific  restimulation  (i.e., 
by  the original  stimulating,  but  not  responding,  cell).  In  fact,  many  of the  primed 
cells were highly discriminatory  reagents with a  bimodal distribution  of positive and 
negative  responses,  suggesting  that  they  recognized  predominantly  a  single  antigen 
(or a cluster of highly associated  antigens). 
Analysis of the responses revealed  that the specificity  of all 22 reagents tested  (in a 
total of 308 different responder-stimulator  combinations)  could be explained  in terms 
of recognition  of five distinct  antigens  (either singly or in  pairs).  Table  II  illustrates STEPHEN SHAW, ARMEAD H. JOHNSON, AND GENE M.  SHEARER  569 
that at least two different reagents could be identified which defined each of the five 
antigens, designated SB1 through SB5. Four lymphocyte populations that had been 
primed to DRw antigens were included as controls in this experiment. Assignment of 
positive and negative was made on the basis of cluster analysis to achieve objectivity 
in the scoring of results.  However, the results were sufficiently clear that  inspection 
would have been almost as effective in making assignments; in the experiment shown, 
65  out  of 67  of the positive assignments  were made  in  combinations with  relative 
responses ~60%, and 126 out of 129 of the negative assignments were in combinations 
with relative responses ~40%. 
Each  SB  antigen  was  identified  with  two  different  PLT  reagents;  there  was 
concordance between the results with the two different reagents in 69 out of the 70 
pairs of SB typing results.  8 of the  14 donors could be unequivocally assigned  two 
specificities; 6 of the  14 were assigned only one specificity. Furthermore, the results 
were internally consistent in that the specificity of the primed lymphocytes could be 
predicted on the basis of the SB antigen assignment  of the original responder and 
stimulator cells (e.g., S 11 anti-H9 is an SB2,5 anti-SB 1,2; and, as predicted, recognizes 
only SB 1). 
Our results confirmed the reports of others (20-22) that DR antigens (or antigens 
very highly associated with them) can induce stimulation in secondary proliferative 
responses. The data in this experiment and others (data not shown) suggest that the 
single apparent disparity between serotyping and PLT (donor F2) reflects difficulty 
in  scoring  positives  and  negatives  in  PLT  rather  than  a  difference between  the 
antigens recognized in PLT and those recognized serologically. Results with D/DR- 
discordant  donors  like  R5  support  the  conclusion  that  the  DR  antigen  itself can 
stimulate strong secondary proliferation. 
Comparison of the assignments  of SB antigens and  DR  antigens  for each donor 
reveals that there is no consistent relationship between a  donor's HLA-DR antigens 
and his SB antigens. The SB antigens are clearly not subsets (or splits) of the known 
D-region antigens,  because it  is  impossible to make a  consistent  assignment  of SB 
antigens  as subgroups  of Dw,  DRw,  or MB  alleles.  Furthermore, the  finding that 
none of the five donors matched for A 1,2,B7,8,  and Dw/DRw2,3 are also identical for 
SB suggest that there may not even be a very strong linkage disequilibrium between 
HLA-DR and SB antigens. 
The mean proliferative response for specific restimulation for the SB reagents was 
16,900 cpm compared with a mean response of 15,900 cpm for the DR reagents. Thus, 
both  series of antigens  can  induce  a  strong  secondary proliferative response.  It  is 
noteworthy that  when  lymphocytes are primed concurrently to SB and  DR,  there 
often  is  a  strong  preferential  response  to  the  DR  specificity, as  illustrated  by  the 
DRw4-directed PLT (Table II); although this priming combination would also allow 
recognition of SB4, there is little if any response to SB4 by these primed cells.  (Results 
of other experiments demonstrate that  lymphocytes primed concurrently against  a 
DR and SB specificity sometimes recognize both [S. Shaw, A. H. Johnson, and G. M. 
Shearer. Unpublished observations.].) 
Failure to Find Alloantisera Identifying SB.  Cells  from the donors listed  in  Table I 
were analyzed with a wide variety of B cell antisera including the Eighth International 
Workshop (Los Angeles, 1980) genetic and disease sets plus 50 additional antisera on 
a local tray. No antisera were found whose pattern of reactivity correlated well with 570  A NEW SEGREGANT SERIES OF  HUMAN  B CELL ALLOANTIGENS 
TABLE III 
The Gene(s) Encoding SB Antigens SBI, 3, and 4 Map Centromeric to HLA-B in Two HLA-B/D 
Recombinant Families 
Percent relative response when restimulated with cells from donor with 
haplotypes indicated 
Priming  Primed  cells 
antigens  Family A  Family P 
cd*  bc  bc/d  bd  ad  cd  ac  ac  ac  ac  a/bc  bc 
SB1  Sit H9~  107  62  3  6  3  12  108  103  86  111  16  15 
+§  +  ....  +  +  +  +  --  _ 
SB2  F2 BI7  3  39  64  75  1  26  12  13  9  19  13  10 
-  +  +  +  ...... 
SB3  PMI MI4  2  1  1  3  2  13  13  9  8  11  84  63 
........  +  + 
SB4  FBI1 FB6  170  9  166  181  172  223  9  7  9  19  11  17 
+  -  +  +  +  +  .... 
SB5  HgsII  17  3  5  11  5  21  11  8  5  11  17  14 
* Haplotype characteristics were as follows: 
Family A.  Family P. 
a A 1-B7-DRw2-MB  l-Dw2  a A 1-BS-DRw3-Dw3 
b A2-Bw5  I-DRw2-MB  1-Dblank  b Aw24-Bblank-Dub  15-Dblank 
c Aw30-Bw44-DRw7-MB2-Dw7  c A2-B  18-DRw2-Dw2 
d Aw26-Bw38-Dub  15-MBblank-DwBSK  d Aw23-B7-DRw6-Dblank 
c/d Aw30-Bw44-Dub  15-MBblank-DwBSK  a/b A 1-B8-Dub  15-Dblank 
:~ Designates the responding cells and the stimulating cells that were used to generate the primed cells. 
§ Designates assignment as positive (+) or negative (-) stimulation by cluster analysis. 
the SB specificities assigned by PLT. More extensive screening of unselected antisera 
is in progress. 
HLA-linkage Studies.  To determine whether the SB antigens are coded by HLA- 
linked genes, segregation analysis was  performed  in seven families, and  the  results 
were consistent with HLA linkage in all families. Table III illustrates the findings in 
the two informative HLA-B/D recombinant families. The data from family A indicate 
segregation of SB 1 with haplotype c, SB2 with haplotype b, and SB4 with haplotypes 
a  and  d;  the  HLA-B/D  recombinant sibling has  inherited  the  portion  of the  d 
haplotype centromeric to HLA-B and, with it, the SB4 marker from that haplotype 
(rather than the SB 1 marker from the c haplotype). The data from family P. indicate 
segregation of SB 1 with haplotype a, SB3 with haplotype b  and SB4 with haplotype 
d. The recombinant acquired that portion of the b  haplotype centromeric to HLA-B, 
and with it the SB3 marker of the b  haplotype (rather than the SB1  marker of the a 
haplotype). These family studies indicate that  SB  antigens 1,  2,  3, and 4  are  HLA 
linked and map the gene(s) encoding SB1, 3, 4 centromeric to HLA-B. 
These family studies demonstrate two other features of the SB antigens. First, they 
confirm the conclusions from population studies that DR and SB are distinct antigens, 
because  they  demonstrate  that  the  SB1  antigen  segregates  with  different  DRw 
antigens (DRw3 and DRw7) on different haplotypes. Furthermore, they demonstrate STEPHEN SHAW, ARMEAD H. JOHNSON,  AND GENE M.  SHEARER 
TABLE IV 
CML Against Two Distinct Series of B Cell Antigens 
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Percent lysis on B cell  lines from donors with HLA-DRw  serotype  indicated  Percent 
lysis of 
Priming  F.ffectors  stimulators' 
antigens  H9  MI4  PMI  W7  R5  BI7  F2  LI0  P6  H7  K4  FI 
2,3  2,3  2,3  2,3  2,3  2,4  2,4  2,2  2,5  3,?6  1,3  4,6  T  vmpho- 
blasts 
SBI  SI I  anti-H9  40  7  4  50  8  2  5  5  I  3  27  I  7 
4-*  --  4-  .....  +  -- 
FB6 anti-FB I I  46  16  10  56  20  5  17  7  4  7  36  4  I I 
+  --  4-  .....  + 
SB2  W7 anti-H9  33  3  ,51  3  37  34  3  4  0  3  5  48  4 
4-  +  -  4-  4-  .....  4- 
F2 anti-Bl 7  45  10  64  14  40  46  6  12  5  6  I0  55  14 
4-  4-  -  4-  4-  .....  4- 
SB3  W7 anti-MI4  12  33  13  6  48  8  10  13  5  2  5  1  6 
-  4-  -  -  4-  ...... 
PMI  anti-MI4  8  44  I  5  56  2  4  3  0  2  6  0  6 
4-  -  ~  4-  ..... 
SB4  FBI 1 anti-FB6  13  22  51  35  12  32  39  38  22  42  3  43  10 
-~;  +  +  +  +  +  -~  +  -  + 
SB5  BI7 anti-F2  10  8  2  II  4  4  52  3  3  2  7  5  11 
-  ~  4-  .... 
DRw2  FI  anti-B17  53  42  58  75  50  53  57  57  33  5  4  3  15 
4-  +  +  4-  +  4-  +  4-  4- 
DRw3  (+SBI)  F2 anti-W7  50  40  65  65  50  3  3  2  2  50  37  22  17 
4-  4-  +  4-  +  ....  +  + 
* Designates assignment as positive (+) or negative (-) cytotoxicity  by cluster analysis. 
Designates the only combinations in whom the PLT assignment of SB did not correlate with the assignment by 
cytotoxicity. 
that  the proliferative response to SB is not  restricted by DR antigens. The fact that 
cells of cd haplotype in  family A.  stimulate  the  SI1  anti-H9 reagent,  even though 
they share no DR antigens with the original stimulating cell, demonstrates that SB 1 
need  not  be  recognized  in  conjunction  with  the  DRw2  or  DRw3  present  on  the 
original stimulating cell. 
Evidence That SB Antigens Are Target Antigens for Cell-mediated Cytotoxicity (CML ).  We 
analyzed these antigens to determine if they can be recognized as target antigens in 
CML,  using principally  the  same donors  as  in  the  proliferative studies.  Cytotoxic 
activity was assayed in secondary responses on target cells from Epstein-Barr virus- 
transformed lymphoblastoid cell lines (Table IV). As controls, cytotoxic effector cells 
were also generated against DR differences. Assignment of positive and negative was 
made on the basis of cluster analysis, although the results were sufficiently clear that 
inspection would have been almost as effective in making assignments. 
Cytotoxicity was generated in the same combinations of responder and stimulators 
that had generated SB-specific proliferation--i.e., those matched for HLA-A, -B, -C, 
-D, -DR, and MB. Killing by these effector cells differed among target cells that were 
identical for HLA-A, -B, -C, -D, -DR, and MB. The distribution of the CML antigens 
among the donors was similar to the distribution  of the antigens defined by prolifer- 
ation. Assignment of antigens by cytotoxic assay agreed with that by PLT in 58 out 
of 60 comparisons. If the two examples of apparent  discordance between CML and 572  A NEW SEGREGANT SERIES OF HUMAN B CELl. AI,I,OANTIGENS 
PLT (Table IV, footnote :~) were consistent, that  would suggest that  the two assays 
detected different antigens; instead, the discordances were limited to the SB4 antigen 
(which is hardest to define) and were not confirmed by other experiments (Table IV; 
and S. Shaw, A. H. Johnson, and G. M. Shearer. Unpublished observations.). 
There was a perfect correlation (24 out of 24)  between the DR assignment of cells 
and their susceptibility to lysis by effector cells generated by DRw2-specific priming 
and  DRw3-specific priming. This confirms previous reports  (23-25)  that  HLA-DR 
antigens per se  (or antigens highly associated with them) can be target antigens for 
allogeneic CML. Again, results relating to the D/DR-discordant donor R5 indicated 
that  the  DR  antigen  itself (in  the  absence of the  concordant  D  specificity)  might 
function as the cytotoxic target antigen. 
Another  feature  of the  cytotoxicity results  is  that  the  SB-specific  killing  is  not 
restricted either by HLA-A, -B, and -C or by HLA-DR. This is evident in the typing 
for SB1 by CML reagents derived from two completely independent responder and 
stimulator cell combinations. The first five targets share all previously defined HLA 
antigens  with  the stimulator  cell  in  the  first  combination  (donor H9)  but  none of 
them with the stimulator cell in the second combination (donor FB6). The magnitude 
of the  killing  by  these effector cells  and  their specificity are  equivalent;  therefore 
matching for A, B, C, D, DR, and MB is not necessary for SB-specific killing. 
To estimate the expression of SB antigens on  B cells relative to that  on T  cells, 
cytotoxicity was compared on B  lymphoblastoid cell lines and  on  PHA-stimulated 
lymphoblasts  (Table  IV).  Both  DR-specific  and  SB-specific  CML  effeetor cells 
preferentially lysed  the  appropriate  B  cell  lines.  The  low  level  of lysis  of the  T 
iymphoblasts by effectors of both specificities could be explained by the expression of 
Ia antigens on a small fraction of lymphoblasts 3 d after stimulation with PHA (26, 
27)  or by  limited  contamination  of the  mitogen-stimulated  cells with  B  cells  and 
macrophages.  The poor lysis of the  T  lymphoblasts  is  not  a  result  of their  being 
insusceptible to lysis, because they were well lysed by control effector cells specific for 
HLA-A and -B antigens (data not shown). Confirmation that the SB antigens are B 
cell antigens is provided by studies showing that the SB-specific CML is inhibited by 
a  monoclonal antiserum specific for an Ia-like molecule (S.  Shaw and  L.  Lampson. 
Manuscript in preparation.). 
Cold- Target Blocking Studies Confirm That Effectors Can Be Generated against Both DR and 
SB.  CML effector cells were generated against  individual DR or SB antigens and 
assayed on B cells of the stimulator cell donor. In a  typical experiment  (Table V), 
each such effector:target combination was assayed both unblocked and in the presence 
of blocking B cells from 12 donors. As in previous studies, the presence or absence of 
blocking was determined by cluster analysis, although inspection would have resulted 
in the same assignments. The results confirmed those observed in direct lysis.  First, 
effector cells raised against DRw2 or DRw3 differences were inhibited by all blocking 
cells that had the appropriate DRw specificity and only by those cells. Second, effector 
cells raised against  individual SB differences were inhibitable only by blocking cells 
that expressed the appropriate SB specificity (assigned by PLT); the concordance in 
assignment  of antigen between direct killing and cold-target inhibition  is complete 
and strengthens the evidence that  the proliferation-inducing antigen and the CML 
antigen are either identical or in very strong linkage disequilibrium. The differences STEPHEN SHAW, ARMEAD H. JOHNSON, AND GENE M.  SHEARER 
TABLE V 
Cold-Target Competition Confirms Two Distinct Series of Antigens 
573 
Percent 
Priming  Effectors  1,,,  sis un- 
antigens  blocked 
Percent  lysls when blo:ked  with B cell  lines fi'um donors with HI,A-I)Rw  scrotype 
indicated: 
H9  MI4  PMI  Sll  W7  BI7  F2  LIO  P6  H7  K4  Fl 
2,~1  2,3  2,3  2,3  2,3  2,4  2,4  2,2  2,5  3,?6  1,3  4,6 
SB l  S 11  anti-H9  47  3  47  41  49  4  46  39  45  46  40  8  44 
+*  -  -  -  +  +  - 
FB6 anti-FBI 1  59  5  48  52  49  3  51  43  48  51  41  6  47 
+  -  _  -  +  +  - 
SB2  W7 anti-H9  59  3  54  I  12  50  4  49  49  52  45  52  2 
+  -  +  +  -  +  + 
F2 anti-BI 7  60  6  49  7  18  43  1  38  43  43  35  46  5 
+  -  +  +  -  +  + 
SB3  W7 anti-M 14  57  61  8  53  54  48  56  50  51  52  43  56  5l 
PMI  anti-M14  65  62  5  67  70  68  70  56  64  62  58  65  65 
SB5  BI 7 anti-F2  66  65  66  61  20  64  65  4  63  60  60  68  67 
DRw2  FI  anti-BI7  66  27  29  21  26  22  5  3  17  15  52  65  ~i2 
+  +  +  +  +  +  +  +  +  --  -- 
DRw3  (+ SBI)  F2 anti-W7  59  19  23  17  30  18  60  56  54  55  16  20  52 
+  +  +  +  +  -  +  +  - 
* Designates assignment as positive (+) or negative (-) blocking  by cluster analysis. 
in  SB-specific blocking by cells  that  are  DR  matched  and  vice versa confirm the 
independence of these two antigens. 
DR-  and  SB-specific  Killing  are  Both  Inhibited  Better  by  B  Cell  Lines  Than  by  T 
Lymphoblasts.  To confirm  that  SB  and  DR  antigens  were  similar  with  respect  to 
greater expression on B cells than on T  cells, B and T  cells were compared in cold- 
target inhibition of DR- and SB-specific CML. Lymphoblastoid B cell lines from the 
stimulator inhibted SB- and  DR-specific lysis almost completely, but  blockers from 
the responder donor did  not  (Table VI).  In  contrast,  PHA  lymphoblasts from the 
stimulator donor blocked poorly, only a little better than did cells from the responder 
donor. 
Analysis  of SB-specific  Killing in an HLA-Recombinant Family.  SB-specific killing was 
analyzed in an unusual  HLA-recombinant family, in which we first identified SBI 
and SB4 in secondary proliferative responses (19).  CML effector cells raised against 
SB 1 and SB4 among donors of phenotype A 1,2,B7,8 were assayed on lymphoblastoid 
B cell lines from five family members and from three control donors (Table VII). The 
data  demonstrate  two  findings.  First,  the  target  antigens  for  CML,  like  the  SB- 
proliferative antigens  in  this  family  (19),  segregate  with  HLA-A  and  -B  markers, 
except  in  the  recombinant  donor.  SB1  segregates  with  the  a  haplotype,  and  SB4 
segregates with the b and d haplotype; the recombinant, who has inherited the HLA- 
A  and -B antigens  from the b  haplotype, has inherited the SB antigen  from the a 
haplotype. Thus,  the  SB1  and  4  antigens  map  to a  region of HLA outside of the 
HLA-A/B  segment;  although  homozygosity  for  other  HLA  markers 
(C2,C4,DR,D,GLO) precludes precise mapping in this family, these cytotoxicity data 574  A  NEW  SEGREGANT  SERIES  OF  HUMAN  B  CELL  ALLOANTIGENS 
TABLE  VI 
Cold-Target Inhibition Studies Indicate Preferential Expression of SB and HLA-DR Antigens on B C¥lls 
Percent lysis when blocked with 
Percent  B cell lines  T  [ymphoblasts 
Priming antigen  Effector  lysis un-  autologous* to  autologous* to 
blocked 
Stimu-  Re-  Stimu-  Re- 
lator  sponder  lator  sponder 
SBI  SI 1 anti-H9  47  3  48  21  32 
FB6 anti-FBl 1  59  5  52  37  47 
SB2  F2 anti-B17  60  1  37  36  46 
W7 anti-H9  59  3  50  ~7  46 
SB3  W7 anti-Ml4  57  8  48  32  48 
PM1 anti-Ml4  65  5  67  42  58 
SB5  B17 anti-F2  66  4  65  36  51 
DRw2  FI  anti-B 17  66  5  62  47  60 
DRw3 (+ SB1)  F2 anti-W7  59  2  56  41  51 
* Autologous except for FB6 which was substituted by B17 and FBI 1 which was substituted by H9. 
TABLE  VII 
CML Studies of SB Antigens in an HLA Recombinant Family: HLA Linkage and Lack of Restriction by 
HLA-A and-B 
Percent lysis on B cell lines from donors 
Priming  Effector  E:T*  Unrelated  Family B 
antigens  ratio 
H9  L10  B17  ac~  a/bc  bc  ad  bd 
SBI  SI1  anti-H9  40:1  23  4  2  40  47  11  31  9 
10:1  19  2  1  32  38  6  22  5 
+§  -  _  +  +  -  +  - 
SB4  H9 anti-Ll0  40:1  3  62  49  6  9  66  46  63 
10:1  1  48  33  2  7  51  26  49 
-  +  +  -  _  +  +  + 
* E:T, effector:target. 
:~ Haplotype characteristics were as follows: 
a A24-B7-DRw4 
b A25-B 15-DRw4 
c A31-B40-DRw4 
d A33-B 17-DRw5 
a/b A25-B15-DRw4 (recombination outside of A-B segment) 
§ Designates assignment as positive (+) or negative (-) cytotoxicity by cluster analysis. 
are consistent  with  the proliferative  studies  showing  that  the  SB antigens  are encoded 
by  genes centromeric  to  HLA-B. 
Second,  these  data  confirm  that  HLA-A  and  -B do  not  restrict  SB-specific  killing. 
The  responder  and  stimulator  cells used  to generate  the CML  effectors share  no HLA- STEPHEN  SHAW,  ARMEAD H.  JOHNSON,  AND GENE  M.  SHEARER  575 
A and -B antigens with the family members. Furthermore, the killing of control cells 
totally HLA-A- and -B-matched with the effectors is comparable to the killing of cells 
from  HLA-A-  and  -B-mismatched  family  members,  indicating  that  there  is  no 
preferential lysis attributable to HLA-A- and -B-matching. 
Discussion 
This study identifies five new HLA-linked antigens by secondary allogeneic prolif- 
erative responses. Each of these antigens can be assigned by at least two discriminatory 
PLT reagents with almost complete concordance between the typing results with the 
two reagents. This study also defines five antigens that can be detected by CML and 
that are preferentially expressed on B cells. The discussion will focus on the following 
issues:  (a) What precedents are there in the literature for such SB antigens? (b) What 
is the relationship between the proliferation-inducing antigens and the CML antigens? 
(c) Are the SB antigens part of a single segregant series?  (d)  What is the relationship 
between the DR antigens and the SB antigens? (e) What may be the functional roles 
of the SB antigens in physiologic immune responses? 
First, what other investigations suggest the existence of antigens similar to those 
described in this study? Since the development of techniques for secondary human 
allogeneic responses (28-30),  it has become apparent  that several different antigens 
stimulate secondary proliferative responses. Both D and DR antigens can independ- 
ently induce secondary responses (20-22). Family studies suggest that antigens distinct 
from the D  and DR antigens can be recognized by PLT (for an A/B recombinant 
family [31], a  B/D  recombinant  family [32],  and  a  D/GLO  recombinant  family 
[33]).  In  addition,  several  laboratories  have  demonstrated  that  priming  between 
donors who are  phenotypically identical  for D/DR  either  in  families, or  between 
unrelated donors can result in generation of PLT reagents that appear to recognize 
HLA-linked antigens distinct from D and DR (22, 34, 35). 
There is no direct precedent for the antigens we have defined by cytotoxic responses. 
There are CML antigens distinct from the known serologically defined HLA-A, -B, 
and -C antigens (36), but these have generally been found on T  cell targets, and are 
thus probably distinct from the SB antigens (which are not well expressed on T cells). 
Studies of primary cytotoxic responses  assayed on  appropriate  targets  (monocytes 
[23], Epstein-Barr virus-transformed B cells [24], and mitogen-stimulated B lympho- 
blasts [25]) demonstrated CML specific for B cell alloantigens, which could be largely 
explained by reactivity with DRw antigens. The failure to detect SB antigens in these 
experiments probably reflects the fact that  cytotoxic responses  to  SB  antigens are 
seldom seen in primary sensitization (S.  Shaw, A. H. Johnson, and G. M. Shearer. 
Unpublished observations.) and the DR-specific CML may overshadow SB-specific 
CML during concurrent sensitization (Tables IV and V, DRw3 reagent). 
Serologic and structural studies provide evidence for two segregant series of B cell 
antigens. Two groups have recently reported isoelectric focusing studies indicating 
two similar but  distinct species of polymorphic B  cell antigens  (13,  14). Serologic 
studies with alloantisera  (9,  10)  and  monoclonal antisera  (11) have also suggested 
more than one kind of human Ia molecule. Collaborative studies are in progress to 
test whether the SB antigens defined functionally in this report are the same as those 
being defined serologically by other laboratories. 
Second, what is the relationship between the proliferation-inducing antigens and 576  A NEW SEGREGANT SERIES OF HUMAN B CELL ALLOANTIGENS 
the CML target antigens? The data suggest that they are identical antigens; however, 
the  data  do  not  exclude  the  possibility  that  they  are  distinct  but  very  strongly 
associated.  If proliferation-inducing  antigens  and  CML  antigens  are  distinct  but 
linked,  they might  not  be  distinguishable  in  the  A1,2,B7,8  donors  because of the 
strong linkage disequilibrium  of A1-B8-DRw3  and  A2-B7-DRw2  haplotypes;  how- 
ever, studies of other donors (such as the family in Table VII and six other unrelated 
donors [data not shown])  demonstrate no convincing discordance. Because the data 
fail to demonstrate any differences, we make the working hypothesis that  they are 
identical. 
Third, are the SB antigens part of a single segregant series? Evidence in this report 
and to be reported subsequently suggests strongly that they comprise a single series. 
Family studies indicate that SB markers can be identified on 29 out of 45 haplotypes 
tested, with no haplotype having two markers. In populations studies, 129 SB antigens 
have been identified on 92  donors with  no donor typing for more than  2 antigens. 
Although the data are still too limited to be tested meaningfully for Hardy-Weinberg 
equilibrium, they strongly suggest these antigens are part of a single segregant series. 
In  addition,  attempts  to  distinguish  between  the  SB  antigens  in  terms  of tissue 
distribution  and  their  function  in  allogeneic responses  have  failed  to  provide any 
evidence that they are different. 
Fourth, what is the relationship between the SB antigens defined in this report, and 
the HLA-DR antigens? There are four similarities between these two series of antigens. 
First, both are coded in  the same region of HLA--centromeric to HLA-B. Second, 
both are preferentially expressed on B cells rather than T  cells. Third, both induce 
strong secondary proliferative responses in mixed lymphocyte culture. Fourth, both 
SB and DR appear to be target antigens for CML (although in both cases it cannot 
be ruled out that the target antigen is distinct and closely associated). 
The only functional difference that we currently recognize between the function of 
DR  and  SB  is quantitative not  qualitative:  DR-specific CML and  D/DR-induced 
proliferation are regularly seen in primary responses, whereas SB-specific CML and 
proliferation is minimal in primary responses (S. Shaw. Unpublished observations.). 
The quantitative rather than  qualitative differences in  the responses to these func- 
tionally similar antigens can be explained by the hypotheses that the amount of the 
SB antigen present on the B cells is substantially less than the amount of DR, or that 
the  size  of the  T  cell  repertoire  that  recognizes  SB  antigens  is  smaller  than  the 
repertoire that recognizes DR antigens. 
Despite  the  functional  similarities  between  the  DR  and  SB  antigens,  they  are 
clearly distinct. Population studies (Table II; and S. Shaw, A. H. Johnson, and G. H. 
Shearer.  Manuscript  in  preparation.)  establish  that  SB antigens  are not  invariably 
present  with  any particular  DR  antigen.  Furthermore,  family studies  (such  as  the 
ones in Table III) demonstrate that a single SB antigen segregates with different DR 
antigens on different haplotypes. However, the molecular relationship between these 
antigens remains unclear. We favor the hypothesis that  DR and SB are located on 
distinct molecules, but further studies will be required to test the alternate possibility 
that DR and SB are independent determinants on the same molecule. 
Fifth, what may be the role of SB antigens in responses to modified-self antigens? 
This report demonstrates that the SB antigens are major histocompatibility antigens 
not only because they are encoded by MHC genes, but also by the functional criteria STEPHEN SItAW, ARMEAD H. JOHNSON, AND GENE M.  SHEARER  577 
that the proliferative and cytotoxic responses to the SB antigens are not restricted by 
HLA-DR or HLA-A, -B. The striking similarities between the SB and DR antigens 
suggest that these two segregant series of antigens are products of duplicated ancestral 
genes. We have already established that they function in qualitatively similar ways in 
allogeneic proliferative and cytotoxic responses. We expect that DR and SB antigens 
will be found to have functionally similar roles in responses to modified self antigens. 
Specifically, we anticipate that SB antigens will restrict clones of T  cells proliferating 
in response to foreign antigen, as has been shown for DR antigens (37, 38). Further- 
more, SB antigens will probably restrict certain clones of cytotoxic T  cells responding 
to  foreign antigen,  as we  have recently suggested  for DR  in CML specific for the 
hapten trinitrophenyl (39). We expect that in modified-self responses, as in ailogeneic 
responses, the SB-restricted component will be smaller than the HLA-DR-restricted 
component.  However,  in  selected  responses,  SB  may  be  the  dominant  restriction 
antigen.  Finally,  SB  antigens,  like  DR  antigens  (40),  may  prove to  be  important 
markers of disease risk, or even to be involved directly in the pathogenesis of certain 
diseases. 
Summary 
Five new histocompatibility antigens, designated secondary B cell or (SB) antigens, 
have been  identified by secondary allogeneic proliferative and  cytotoxic responses. 
The reagents used to define the SB antigens are lymphocytes primed between donors 
matched  for  all  known  HLA  antigens.  The  SB  antigens  stimulate  weak  primary 
allogeneic proliferative responses (a mean relative response of  8%) but strong secondary 
proliferative  responses.  Strong  secondary  cell-mediated  cytotoxicity  is  generated 
against  target antigens  that  are indistinguishable  from the  SB antigens defined by 
proliferation. Studies by direct lysis and by cold-target inhibition indicate that these 
target  antigens  are  preferentially expressed on  B  cells  relative to T  cells.  The  SB 
antigens segregate with  HLA, and  the gene(s) encoding the SB 1, 3, and 4 antigens 
maps centromeric to HLA-B. The SB antigens are major histocompatibility antigens 
not  only because  they  are  encoded  by  major  histocompatibility  complex  (MHC) 
genes, but also by the functional criteria that the proliferative and cytotoxic responses 
to SB antigens are not restricted by HLA-DR or HLA-A, -B.  Parallel studies of the 
SB antigens and the DR antigens indicate that there are striking functional similarities 
between SB and DR antigens with respect to:  (a) their preferential expression on B 
cells, (b) their function in secondary allogeneic proliferative and cytotoxic responses, 
and  (c)  the  location  of their  structural  gene  within  the  MHC.  However, the  SB 
antigens and the DR antigens are clearly distinct antigens, because population studies 
indicate that they can occur independently, and family studies indicate that specific 
SB antigens segregate with HLA haplotypes having different D and DR specificities. 
Our data are consistent with the hypotheses that the SB antigens are a new segregant 
series of B cell alloantigens, and  that  the SB gene and  the DR  gene derive from a 
duplicated ancestral gene. 
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